Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study.
N2 disease
induction therapy
non-small-cell lung cancer
radical resection
stage III
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
08
07
2021
revised:
23
02
2022
accepted:
10
03
2022
pubmed:
10
4
2022
medline:
4
5
2022
entrez:
9
4
2022
Statut:
ppublish
Résumé
There is lack of consensus whether neoadjuvant chemoradiotherapy (CHT/RT) is superior to neoadjuvant chemotherapy (CHT) alone in patients with potentially resectable stage III/N2 non-small-cell lung cancer (NSCLC). We retrospectively evaluated clinical parameters and outcomes in patients with clinical stage III/N2 NSCLC treated with neoadjuvant CHT/RT versus CHT followed by surgery. Nearest-neighbor propensity score (PS) matching was used to correct for pretreatment differences. A total of 84 patients were enrolled. Thirty-four (40%) and 50 (60%) patients received CHT/RT or CHT followed by curative-intent surgery, respectively. Overall 90-day mortality and morbidity were 0% versus 0.04% and 21% versus 18%, respectively, with no significant difference between the CHT/RT and the CHT-alone cohorts (P = 0.51 and P = 0.70). In the PS-matched cohort, complete pathological response was recorded in 25% after CHT/RT versus 0% after CHT at the time of surgery. Patients receiving neoadjuvant CHT/RT exhibited significantly better 5-year disease-free survival (DFS) [45% versus 16% CHT group; hazard ratio (HR) 0.43, P = 0.04]; 5-year overall survival (OS) was 75% after CHT/RT and 21% after CHT (HR 0.37, P = 0.001). CHT/RT more often induced pathological mediastinal downstaging (P = 0.007), but CHT/RT remained the only independent factor for DFS and OS and did not depend on mediastinal downstaging. In this retrospective PS-matched long-term analysis, neoadjuvant CHT/RT conferred improved DFS and OS compared with CHT alone in stage III/N2 NSCLC. These highly challenging results require confirmation in well-designed randomized controlled trials conducted at highly specialized thoracic oncology centers.
Sections du résumé
BACKGROUND
There is lack of consensus whether neoadjuvant chemoradiotherapy (CHT/RT) is superior to neoadjuvant chemotherapy (CHT) alone in patients with potentially resectable stage III/N2 non-small-cell lung cancer (NSCLC).
PATIENTS AND METHODS
We retrospectively evaluated clinical parameters and outcomes in patients with clinical stage III/N2 NSCLC treated with neoadjuvant CHT/RT versus CHT followed by surgery. Nearest-neighbor propensity score (PS) matching was used to correct for pretreatment differences.
RESULTS
A total of 84 patients were enrolled. Thirty-four (40%) and 50 (60%) patients received CHT/RT or CHT followed by curative-intent surgery, respectively. Overall 90-day mortality and morbidity were 0% versus 0.04% and 21% versus 18%, respectively, with no significant difference between the CHT/RT and the CHT-alone cohorts (P = 0.51 and P = 0.70). In the PS-matched cohort, complete pathological response was recorded in 25% after CHT/RT versus 0% after CHT at the time of surgery. Patients receiving neoadjuvant CHT/RT exhibited significantly better 5-year disease-free survival (DFS) [45% versus 16% CHT group; hazard ratio (HR) 0.43, P = 0.04]; 5-year overall survival (OS) was 75% after CHT/RT and 21% after CHT (HR 0.37, P = 0.001). CHT/RT more often induced pathological mediastinal downstaging (P = 0.007), but CHT/RT remained the only independent factor for DFS and OS and did not depend on mediastinal downstaging.
CONCLUSIONS
In this retrospective PS-matched long-term analysis, neoadjuvant CHT/RT conferred improved DFS and OS compared with CHT alone in stage III/N2 NSCLC. These highly challenging results require confirmation in well-designed randomized controlled trials conducted at highly specialized thoracic oncology centers.
Identifiants
pubmed: 35397435
pii: S2059-7029(22)00084-9
doi: 10.1016/j.esmoop.2022.100466
pmc: PMC9058885
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100466Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have declared no conflicts of interest.
Références
Ann Thorac Surg. 2008 Nov;86(5):1626-30
pubmed: 19049761
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
J Thorac Oncol. 2019 Nov;14(11):1962-1969
pubmed: 31442497
J Clin Oncol. 2019 Sep 1;37(25):2235-2245
pubmed: 31194613
J Clin Oncol. 2015 Dec 10;33(35):4194-201
pubmed: 26527789
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
Ann Thorac Surg. 2018 Apr;105(4):1008-1016
pubmed: 29453000
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Lancet Oncol. 2008 Jul;9(7):636-48
pubmed: 18583190
Clin Transl Oncol. 2019 Jun;21(6):735-744
pubmed: 30430394
J Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276
pubmed: 30718052
Lancet Oncol. 2009 Aug;10(8):785-93
pubmed: 19604722
J Thorac Cardiovasc Surg. 2011 Jan;141(1):48-58
pubmed: 21092990
J Thorac Oncol. 2015 Dec;10(12):1675-84
pubmed: 26709477
World J Surg Oncol. 2018 Jan 16;16(1):8
pubmed: 29338734
Lancet. 2015 Sep 12;386(9998):1049-56
pubmed: 26275735
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Cancer. 2012 Dec 15;118(24):6126-35
pubmed: 22674529
Eur J Cardiothorac Surg. 2020 Apr 1;57(4):740-746
pubmed: 31638692
J Thorac Dis. 2015 Sep;7(9):1616-23
pubmed: 26543609
Clin Lung Cancer. 2022 May;23(3):e247-e251
pubmed: 34819266
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426
J Natl Cancer Inst. 2007 Mar 21;99(6):442-50
pubmed: 17374834
Ann Thorac Surg. 2017 Jan;103(1):281-286
pubmed: 27623273
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
J Clin Oncol. 2003 May 1;21(9):1752-9
pubmed: 12721251
Ann Oncol. 2015 Aug;26(8):1573-88
pubmed: 25897013
BMC Cancer. 2019 May 2;19(1):413
pubmed: 31046714